EMA Authorised: Kymriah (tisagenlecleucel) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Kymriah (tisagenlecleucel) for additional indications in precursor B-cell lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Precursor Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Status: Authorised. Therapeutic area: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Lymphoma, Large B-Cell, Diffuse. MAH: Novartis Europharm Limited. Decision date: 06/11/2025. Orphan medicine